Roche to Acquire GenMark Diagnostics for $1.8B
Shots:
- Roche to acquire all outstanding shares of GenMark’s for $24.05/ share in cash- making a total deal value of $1.8B with a premium of ~43% to GenMark’s closing price on Feb 10- 2021. The acquisition is expected to be completed in Q2’21
- The acquisition will boost Roche’s molecular diagnostics portfolio and will expand the global reach of GenMark’s products
- GenMark deliver molecular diagnostic tests designed to detect multiple pathogens from a single patient sample and its respiratory pathogen panels complement Roche’s COVID-19 diagnostics solutions
Ref: GlobeNewswire | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com